Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Results from the phase 3 MOMENTUM trial show that patients with myelofibrosis receiving momelotinib—a first-in-class activin A receptor type 1, JAK1, and JAK2 inhibitor—achieved clinically significant improvements in myelofibrosis-associated symptoms, compared with those receiving danazol. Using the Myelofibrosis Symptom Assessment Form, 32 patients (25%) in the momelotinib group reported a ³50% reduction in Total Symptom Score vs. 6 patients (9%) in the danazol group (proportion difference 16% [95% CI: 6-26], P = 0.0095).